NRIX Nurix Therapeutics, Inc.
Financings ·
Nurix raised its Piper Sandler at-the-market program to $413.65 million, of which $113.65 million has already been sold. Its fiscal 2025 net loss was $264.5 million and cash used in operations was $249.5 million.
We have not published a story on Nurix Therapeutics yet. When there is news, it will appear here.
Nurix Therapeutics is a clinical-stage biopharmaceutical company focused on targeted protein degradation medicines for patients with cancer and inflammatory diseases. The company describes its DEL-AI discovery engine as an artificial intelligence-integrated platform that combines DNA encoded library hit-finding with ligase expertise. Its wholly owned clinical pipeline includes bexobrutideg (NX-5948), a highly selective degrader of Bruton's tyrosine kinase (BTK) in a Phase 2 study in relapsed or refractory chronic lymphocytic leukemia (CLL); zelebrudomide (NX-2127), a dual degrader of BTK and the IKZF1 and IKZF3 transcription factors in a Phase 1a/1b study in relapsed or refractory B-cell malignancies; and NX-1607, an inhibitor of the CBL-B E3 ligase in a Phase 1a/1b study across oncology indications. Its partnered pipeline includes a clinical-stage IRAK4 degrader (NX-0479/GS-6791) and a preclinical STAT6 degrader. The company names collaborations with Gilead Sciences, Sanofi and Pfizer, and the text says it had received $482.0 million in non-dilutive financing from its collaborators as of November 30, 2025.
| Product or program | What it is | Stage |
|---|---|---|
| bexobrutideg | Oral selective BTK degrader for relapsed or refractory B-cell malignancies | Phase 2 |
| zelebrudomide | Oral dual degrader of BTK and IKZF1 and IKZF3 | Phase 1a/1b |
| NX-1607 | Oral CBL-B inhibitor for solid tumors and other oncology indications | Phase 1a/1b |
| Line | FY ended Nov 30, 2025 | FY ended Nov 30, 2024 |
|---|---|---|
| Research and development | $316.9 million | $221.6 million |
| Net income (loss) | -$264.5 million | -$193.6 million |
| Cash from operations | -$249.5 million | -$172.6 million |
| Cash and equivalents | $247.0 million | $110.0 million |
Our latest story on this, dated Mar 6, 2026: "Nurix Therapeutics lifts its at-the-market program total to $413.65 million". The story links the filing or release it is based on. Read the story.
Nurix Therapeutics, Inc. trades under the ticker NRIX on NASDAQ.
Nurix Therapeutics, Inc. is listed on NASDAQ.
The SEC Central Index Key (CIK) for Nurix Therapeutics, Inc. is 1549595. Its filings are on SEC EDGAR.
109,249,814 shares as of 2026-09-30, per the cover page of its 10-Q filed 2026-10-13.
Our directory records Nurix Therapeutics, Inc. under United States.
Our directory classifies Nurix Therapeutics, Inc. as: Biotechnology. This is a directory classification, not a description of the pipeline.
The ISIN recorded for Nurix Therapeutics, Inc. is US67080M1036.
aibio.space lists Nurix Therapeutics, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
SEC records list its state or country of incorporation as DE.
Nurix Therapeutics is a clinical-stage biopharmaceutical company focused on targeted protein degradation medicines for patients with cancer and inflammatory diseases. The company describes its DEL-AI discovery engine as an artificial intelligence-integrated platform that combines DNA encoded library hit-finding with ligase expertise.
bexobrutideg: Oral selective BTK degrader for relapsed or refractory B-cell malignancies Stage: Phase 2.
zelebrudomide: Oral dual degrader of BTK and IKZF1 and IKZF3 Stage: Phase 1a/1b.
Nurix Therapeutics, Inc. reported a net loss of $264.5 million for the fiscal year ended Nov 30, 2025, and used $249.5 million of cash in operations, per its annual report to the SEC.
$316.9 million in the fiscal year ended Nov 30, 2025, per its annual report.
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio